| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
NPCE
NeuroPace
|
Mar 06, 2026 | BUY |
Strong Buy
+13.4% avg upside
11 analysts
|
$19.00
21.46% Upside
|
+12.2% |
|
IART
Integra Lifesciences
|
Feb 27, 2026 | HOLD |
Buy
+137.0% avg upside
21 analysts
|
$12.00
31.82% Downside
|
+54.7% |
|
GMED
Globus Medical
|
Feb 26, 2026 | BUY |
Strong Buy
+22.3% avg upside
24 analysts
|
$104.00
31.26% Upside
|
-16.9% |
|
ALGN
Align Tech
|
Feb 05, 2026 | BUY |
Strong Buy
+58.0% avg upside
21 analysts
|
$200.00
9.89% Upside
|
-1.2% |
|
CNMD
Conmed
|
Jan 29, 2026 | HOLD |
Hold
+81.5% avg upside
12 analysts
|
$42.00
28.91% Upside
|
-2.6% |
|
ATEC
Alphatec Holdings
|
Jan 13, 2026 | BUY |
Strong Buy
+116.6% avg upside
22 analysts
|
$28.00
217.78% Upside
|
-50.8% |
|
SOLV
Solventum Corporation
|
Jan 13, 2026 | HOLD |
Buy
+14.3% avg upside
15 analysts
|
$86.00
14.06% Upside
|
-11.3% |
|
XRAY
DENTSPLY SIRONA
|
Nov 07, 2025 | HOLD |
Buy
+171.7% avg upside
25 analysts
|
$12.00
16.23% Upside
|
-4.1% |
|
ENOV
Enovis
|
Nov 07, 2025 | BUY |
Strong Buy
+217.5% avg upside
37 analysts
|
$42.00
91.10% Upside
|
-11.3% |
|
HSIC
Henry Schein
|
Aug 06, 2025 | HOLD |
Buy
+7.4% avg upside
25 analysts
|
$70.00
12.51% Downside
|
+22.4% |
|
NVST
Envista Holdings
|
Mar 07, 2025 | HOLD |
Buy
+13.6% avg upside
19 analysts
|
$19.00
26.74% Downside
|
+45.7% |
|
ISRG
Intuitive Surgical
|
Sep 26, 2023 | BUY |
Strong Buy
+29.5% avg upside
36 analysts
|
$386.00
5.04% Downside
|
+67.3% |
|
EW
Edwards Lifesciences
|
Mar 21, 2016 | BUY |
Strong Buy
+11.7% avg upside
34 analysts
|
$109.00
24.73% Upside
|
+8.4% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.